There are numerous reports on the elevation of vWF in patients with CS as compared with control subjects (4, 7, 46–50), comparison of vWF in active phase and after treatment (38, 48, 51), and the association between vWF promoter polymorphism with vWF level (35, 36, 52). This evidence concerns the gene VWF and Cowden syndrome 1.